Answers are grounded in this paper and cite their sources.
Research reveals HSD17B4's connection to lipid metabolism in tumors, suggesting it as a cancer biomarker and therapy target.
17-β-hydroxysteroid dehydrogenase 4 (HSD17B4), abundantly present in the peroxisomal regions of mammalian cells, is an oxidoreductase that catalyzes the oxidoreduction of steroid substrates. Impairment of lipid metabolism represents one of the most critical metabolic alterations in cancer, with lipid metabolic processes tightly linked to tumor cell proliferation, survival, invasion, and metastasis. HSD17B4 is primarily involved in the regulation of cellular fatty acid and hormone metabolism. Therefore, HSD17B4 is closely related to tumors, but few relevant studies exist. Polymorphisms and methylation of the HSD17B4 gene, as well as acetylation of the HSD17B4 protein, influence its expression and function, impacting cancer progression and therapeutic response. Recent findings also highlight HSD17B4 as a potential therapeutic target and prognostic biomarker in various cancers. Here, we will discuss the latest literature on human HSD17B4 and its clinical implications.
No takes yet. Share an insight, caveat, or question.
Liao et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: